Drug Profile

VY 101

Alternative Names: ReOpt-NK™; ReOpt-NK™ therapy - Vycellix; Retargeted Optimized Natural Killer cell therapy - Vycellix; RONK™; VY-101

Latest Information Update: 28 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Karolinska Institute
Developer Vycellix
Class Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Mar 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
26 Feb 2019 Preclinical trials in Haematological malignancies in USA (Parenteral) (Vycellix pipeline, February 2019)
26 Feb 2019 Vycellix announces intention to submit IND to the US FDA for Haematologic malignancies in 2021 (Vycellix pipeline, February 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com